RedHill Biopharma Ltd., a specialty biopharmaceutical company with a focus on gastrointestinal and infectious diseases, boasts an impressive portfolio of drugs including Movantik, Talicia, and Aemcolo. The company's late-stage investigational development programs include RHB-204, opaganib (Yeliva), RHB-107, RHB-104, RHB-102 (Bekinda), and RHB-106. Among these is opaganib, an SK2 selective inhibitor that has completed Phase 2 studies to treat patients with SARS-CoV-2 severe COVID-19 pneumonia and is also in Phase 2 studies to treat advanced unresectable cholangiocarcinoma and prostate cancer. RedHill Biopharma Ltd. was founded in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.'s ticker is RDHL
The company's shares trade on the NASDAQ stock exchange
They are based in Tel-Aviv, Israel
There are 51-200 employees working at RedHill Biopharma Ltd.
It is https://www.redhillbio.com/
RedHill Biopharma Ltd. is in the Healthcare sector
RedHill Biopharma Ltd. is in the Biotechnology industry
The following five companies are RedHill Biopharma Ltd.'s industry peers: